NF-κB activity is elevated in a high proportion of cancers, particularly advanced cancers that have been treated previously. Cytotoxic treatment selects for such up-regulation inasmuch as NF-κB promotes transcription of a large number of proteins that inhibit both the intrinsic and extrinsic pathways of apoptosis; NF-κB also boosts expression of mdr1, which expels many drugs from cells. Indeed, high NF-κB activity appears to be largely responsible for the chemo-and radioresistance of many cancers. Thus, agents that suppress NF-κB activity should be useful as adjuvants to cytotoxic cancer therapy. Of the compounds that are known to be NF-κB antagonists, the most practical for current use may be the nonsteroidal anti-inflammatory drugs aspirin, salicylic acid, and sulindac, each of which binds to and inhibits IκB kinaseβ, a central mediator of NF-κB activation; the low millimolar plasma concentrations of salicylate required for effective inhibition of this kinase in vivo can be achieved with highdose regimens traditionally used to manage rheumatic disorders. The gastrointestinal toxicity of such regimens could be minimized by using salsalate or enteric-coated sodium salicylate or by administering misoprostol in conjunction with aspirin therapy. Presumably, best results would be seen if these agents were administered for several days prior to a course of chemo-or radiotherapy, continuing throughout the course. This concept should first be tested in nude mice bearing xenografts of chemoresistant human tumors known to have elevated NF-κB activity. Ultimately, more complex adjuvant regimens can be envisioned in which salicylates are used in conjunction with other NF-κB antagonists and/or agents that target other mediators of down-regulated apoptosis in cancer, such as Stat3; coadministration of salicylate and organic selenium may have intriguing potential in this regard. These strategies may also have potential as adjuvants to metronomic chemotherapy, which seeks to suppress angiogenesis by targeting cycling endothelial cells in tumors.
Up-regulated NF-κB Activity Promotes Chemoresistance in Many Cancers
In a high proportion of advanced human cancers, NF-κB activity is constitutively up-regulated. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] This phenomenon may reflect increased expression of various Rel/NF-κ subunits, mutations that abrogate the expression or inhibitory activity of IκBs, or, most commonly, up-regulation of upstream signaling pathways that activate NF-κB via the signalsome (IκB kinase). 1 Activated NF-κB promotes transcription of a diverse array of proteins that can stimulate proliferation (cyclin D1, c-myc), provoke angiogenesis (vascular endothelial growth factor [VEGF], interleukin-8), and encourage cellular migration and spread (matrix metalloproteinase-9, cyclooxygenase [cox]-2, urokinasetype plasminogen activator, intercellular cell adhesion molecule-1). [11] [12] [13] [14] [15] [16] [17] [18] However, its most substantial impact may be on apoptosis: activated NF-κB promotes transcription of a wide range of proteins that suppresses both the intrinsic (mitochondrial-mediated) and extrinsic pathways of apoptosis; these include bcl-2, bcl-xL, bfl-1, survivin, c-FLIP, TRAF1, IAP1/2, and XIAP. 19, 20 Moreover, NF-κB activity reduces the stability of the mRNA coding for GADD45, a protein that appears to play an obligate role in apoptosis. 21, 22 Since most cytotoxic chemotherapeutic drugs kill their targets by apoptosis, it is not surprising that upregulation of NF-κB activity often plays a key role in the evolution of chemoresistance and that prior therapy tends to select for such up-regulation. [23] [24] [25] [26] [27] [28] [29] In this regard, it is notable that NF-κB up-regulation is commonly noted in breast and prostate cancers that no longer respond to antagonists of estrogen or androgen receptors, respectively. 30, 31 NF-κB can also promote chemoresistance by inducing transcription of mdr1 (also known as P-glycoprotein), an adenosine triphosphate (ATP)-binding cassette protein that functions to expel a range of xenobiotic chemicals from the cell, including many chemotherapeutic drugs. 32, 33 Thus, it is widely suspected that practical pharmaceutical measures for suppressing NF-κB activity could amplify the chemosensitivity and abrogate the chemoresistance of the high proportion of advanced tumors in which NF-κB is up-regulated. Indeed, such a phenomenon has been demonstrated repeatedly in cell culture studies, as well as in tumorbearing rodents. 10, [34] [35] [36] [37] Activation of NF-κB generally requires activation of the signalsome, a trimeric protein complex containing 2 enzymes-IκB kinase-α and -β-that when activated by upstream kinases, promote the nuclear translocation and transcriptional activation of NF-κB dimers. 38 IκB kinase-β appears to play the most crucial role, as it phosphorylates, and thereby destines for proteosomal destruction, the IκB factors that bind to NF-κB and retain it in the cytoplasm. 39 This kinase also catalyzes a phosphorylation of the p65 (RelA) subunit, required for optimal protranscriptional activity of the NF-κB dimers featuring this subunit. Under certain circumstances, activated IκB kinase-α also can perform this phosphorylation. 39 The kinases that promote signalsome activation include NF-κB-inducing kinase (downstream from various cytokine receptors), MEKK1, and Akt. [40] [41] [42] [43] In many cancers, up-regulation of growth factor signaling leads to constitutive activation of the PI3K-Akt pathway, which in turn promotes constitutive activation of signalsomes and NF-κB. [43] [44] [45] [46] [47] [48] [49] 
Targeting NF-κB as an Adjuvant to Cytotoxic Therapy: Potential of Aspirin
Since IκB kinase-β appears to be the final common mediator of NF-κB activation, it is not surprising that various small molecules capable of suppressing NF-κB activity in vitro have been shown to target this kinase. These include parthenolide, the active agent in the anti-inflammatory, antimigraine herb feverfew, 50, 51 as well as the nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin, salicylic acid, and sulindac. 52, 53 Other NSAIDs have no impact on IκB kinase-β; thus, the ability of aspirin, salicylic acid, and sulindac to influence this kinase appears to be entirely unrelated to their cox-inhibitory activities. Aspirin and salicylic acid have been shown to be competitive inhibitors of ATP binding to IκB kinase-β. 52 Parthenolide may have genuine potential in cancer therapy, inasmuch as it has been shown to potentiate response to docetaxel in nude mice implanted with a human breast tumor. 54 Nonetheless, it is not currently available except as a component of feverfew extracts, and the parthenolide content of commercial feverfew extracts varies by more than 100-fold, with the maximal content observed being 3 mg per capsule. 55 In contrast, with respect to aspirin and salicylic acid, there is considerable previous clinical experience with these agents in high doses, so they may represent the most practical current clinical option for limiting NF-κB activation. In cell cultures, 50% inhibition of IκB kinase activity was achieved at an aspirin concentration of 80 µM-an effect very similar in potency to aspirin's effect on cox (IC 50 said to be 50-100 µM). 52 However, since 80% to 90% of aspirin (or salicylate) in plasma is bound to proteins, primarily albumin, it can be anticipated that low millimolar plasma concentrations of salicylates might be required for substantial inhibition of NF-κB in vivo. Indeed, such concentrations are achieved by the high-dose regimens used traditionally in the management of rheumatoid arthritis; Goodman and Gilman's cites 5 to 8 g aspirin daily, administered in multiple daily doses of 1 g each, as optimal for management of polyarthritis in adults. 56 Alternatively, a comparable intake of entericcoated sodium salicylate would be expected to have a comparable impact on NF-κB but would be much less likely to provoke gastrointestinal (GI) ulceration 57, 58 and would not cause irreversible suppression of platelet function (of importance to treated cancer patients who intermittently may become thrombocytopenic). Indeed, salicylic acid is only a weak competitive inhibitor of cox, and it is doubtful whether such inhibition contributes importantly to salicylate's clinical impact on inflammatory disorders. [59] [60] [61] The much greater impact of aspirin therapy on cox activity reflects acetylation of an active site serine that causes permanent and complete inhibition of the enzyme. Although salicylic acid can indeed irritate the stomach (for reasons apparently unrelated to cox inhibition), this problem can be minimized by administering salicylate in enteric-coated form or by using salsalate, a dimer condensation product of salicylic acid that remains insoluble in the acidic stomach but hydrolyzes in the intestine to yield free salicylic acid, which is then readily absorbed. [62] [63] [64] [65] [66] Clinical doses of salsalate-usually 3 g daily-have only a modest and rapidly reversible impact on systemic prostanoid production; as compared to aspirin, salsalate is far less likely to provoke gastric bleeding and has only a small and transient effect on platelet function. 60, 63, 67 Thus, the chief tolerance problem with salsalate is reversible ototoxicity. 68, 69 One recent clinical study stands out as particularly pertinent: Shoelson and colleagues administered 7 g aspirin daily for a period of 2 weeks to a group of individuals with type 2 diabetes. 70 This study was undertaken in light of recent evidence that IκB kinase-β may be a key mediator of fat-induced insulin resistance [71] [72] [73] [74] ; indeed, the study showed that insulin sensitivity improved significantly in these patients with diabetes during aspirin administration. Since aspirin doses of this magnitude can damage the GI tract, the investigators coadministered misoprostol, 200 µg 4 times daily; misoprostol is a stable analog of prostaglandin E (PGE) that has been shown to protect the GI tract from NSAID toxicity. 75 Under these conditions, no gastric bleeding was observed. The chief side effects were tinnitus and slight hearing impairment, which were said to become less notable as the study proceeded and remitted after the study's conclusion; there was also some mild GI cramping presumably attributable to the misoprostol. Otherwise, the regimen was well tolerated. The favorable impact of this regimen on glycemic control suggests that it did indeed achieve significant clinical inhibition of IκB kinase-β. An analogous insulin-sensitizing effect has been observed in obese diabetic rats treated with 120 mg/kg aspirin daily, administered by continuous subcutaneous infusion. 72 In a more recent communication, Shoelson et al stated that at 4.5 g daily, salsalate appears to be as effective as high-dose aspirin for improving insulin function in persons with diabetes. 76 In numerous cell culture studies, aspirin, salicylate, or sulindac have been shown to diminish NF-κB activity in cancer cells, associated with up-regulation of apoptosis and/or a decrease in proliferation or invasiveness. [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] One of these studies reported that salicylic acid abrogated the radioresistance of primary tumors derived from mice transgenic for the Tax protein (a product of the human T-cell leukemia virus that promotes NF-κB activation). 79 Sodium salicylate and sulindac have been shown to up-regulate the apoptotic response to tumor necrosis factor-α in pancreatic and non-small-cell lung cancer cells, respectively. 77, 78 Remarkably, however, there do not appear to be any published studies (traceable on Medline, at least) that have evaluated the ability of these NSAIDs to boost the chemotherapeutic responsiveness of human tumor xenografts in immunodeficient mice. (Not unlikely, the fact that these agents are long off patent has something to do with this dearth of data!) One discordant report should be cited: in LNCaP cells, but not other prostate cancer cell lines examined, aspirin diminished responsiveness to adriamycin by up-regulating MDR1 90 ; this result is hard to interpret, inasmuch as NF-κB as well as cox-2 activity are thought to up-regulate this protein.
In light of these considerations, the most practical strategy available at present for suppressing NF-κB activity during chemo-or radiotherapy may be coadministration of aspirin, sodium salicylate, or salsalate in high clinical doses; if aspirin is used, it would be prudent to concurrently provide protection to the GI tract with misoprostol, as in the Shoelson study. Presumably, this will be most effective if the aspirin/ salicylate is administered for a few days prior to initiating cytotoxic therapy-so that proapoptotic mechanisms will be up-regulated beforehand-and then continued throughout the course of this therapy. Preclinically, this strategy could most appropriately be assessed in nude mice implanted with xenografts of human tumors known to be relatively chemoresistant and to have elevated NF-κB activity. With respect to the clinical use of misoprostol, a controlled study found that 200 µg 3 times daily provided protection from NSAIDs comparable to that afforded by 4 daily doses, with fewer GI side effects. 83 One proviso should be noted: the response of colorectal cells to aspirin appears to be anomalous; Dunlop and colleagues have repeatedly reported that in certain human colorectal cancer cell lines (but not in other cancer cell lines they have examined), aspirin exposure actually activates NF-κB, promoting its nuclear translocation, an effect that is associated with increased apoptosis. 91, 92 Remarkably, NF-κB-driven reporter gene transcription is repressed by aspirin in these cells, despite the documented increase in nuclear translocation of RelA. How this might influence response to concurrent cytotoxic therapy is not at all clear and requires experimental evaluation. The authors suspect that this phenomenon is directly relevant to the strong anticarcinogenic impact of aspirin on risk for colorectal cancer. In any case, these findings suggest that use of salicylates as an adjuvant to chemotherapy of colorectal cancer may represent a special case requiring separate consideration.
Evidently, salicylate therapy is less than ideal as a clinical tool for modulating NF-κB activity. The potential for adverse effects stemming from concurrent cox inhibition (when aspirin is used), the annoying-albeit transient-ototoxicity, and the need for multiple daily doses are undesirable. It can be anticipated that sooner or later, highly specific pharmaceutical inhibitors of IκB kinase, administrable orally, will become clinically available; a recent review by Karin and colleagues cites a range of agents that are now being evaluated in this regard. 93 It is hoped that some of these agents will be sufficiently well tolerated so that they can be used continuously in the management of cancers with elevated NF-κB activity. However, until such agents become available, it should be borne in mind that high-dose salicylate therapy has been a mainstay of the management of rheumatic disorders for decades 56 and is quite feasible for motivated patients. Moreover, it is hard to understand why high-dose aspirin has not achieved more attention as an option in cancer management given the fact that aspirin inhibits both isoforms of cox and suppresses activation of NF-κB; up-regulation of cox-2 expression and/or increased NF-κB activity contributes to the malignant behavior and chemoresistance of a high proportion of cancers, and, in endothelial cells, both cox activity and NF-κB appear to play an obligate role in angiogenesis. 7, [94] [95] [96] [97] [98] [99] Furthermore, activation of NF-κB in skeletal muscle fibers is a key mediator of the proteolysis that gives rise to muscle wasting in neoplastic cachexia. [100] [101] [102] Almost all studies examining the impact of salicylates on cancer in rodents have assessed chemoprevention rather than control of preexisting tumors.
Complementary Strategies for Addressing NF-kB
It is not likely that tolerable doses of salicylates will achieve total inhibition of IκB kinase-β. Ultimately, it may prove feasible to complement aspirin/salicylate therapy with other agents that target up-regulated NF-κB activity. Thus, parthenolide, or various new drugs being developed as NF-κB inhibitors, may emerge as useful adjuncts to salicylates. In this regard, it may be noted that joint exposure of a pancreatic cancer cell line to parthenolide and sulindac-both of which target IκB kinase-β-is more effective for inhibiting NF-κB activity than either agent administered alone. 103 Analogously, aspirin synergized with transfection of wild-type p53 in suppressing NF-κB activity in human colon cancer cells. 83 A range of phytochemicals, including curcumin, epigallocatechin gallate (EGCG), resveratrol, guggulsterone, silibinin, zerumbone, indole-3-carbinol, and evodiamine, have been reported to inhibit activation of IκB kinase/NF-κB in cultured cells; the specific molecular targets of these agents, and the generality of their activity in this regard, remain unclear. 19, 20, [104] [105] [106] [107] [108] [109] [110] Whether any of these compounds will achieve true clinical utility as NF-κB antagonists is somewhat doubtful, as it may not be feasible to achieve and maintain tissue concentrations comparable to those used in vitro; nonetheless, continuing research with these agents should be followed with interest. In particular, it is intriguing that orally administered silibinin can inhibit the growth of human prostate and lung cancers in nude mice; moreover, the sensitivity of the lung carcinoma to doxorubicin was amplified by silibinin. [111] [112] [113] Proteasome inhibitors suppress NF-κB activity by preventing the proteasomal degradation of IκB. These have received extensive preclinical evaluation as potential cancer therapies, and one of these, bortezomib, has already achieved approval for use in refractory multiple myeloma. 114 The utility of this agent for countering chemoresistance has been demonstrated in rodent models. [115] [116] [117] Since proteasomes contribute to the turnover of a broad spectrum of cellular proteins, proteasome inhibitors exert a number of effects unrelated to NF-κB modulation. (For example, they increase the activity of hypoxia-inducible factor-1α, which promotes angiogenesis; nonetheless, the net effect of bortezomib therapy has been antiangiogenic in some rodent models. [118] [119] [120] In animal toxicity studies, cardiotoxicity and neurotoxicity are noted. 121 Bortezomib must be administered parenterally; in clinically feasible doses, side effects include low-grade fever, fatigue, thrombocytopenia, peripheral neuropathy, and lowgrade diarrhea. No published studies have tested this agent in conjunction with salicylates; however, there is one report that sulindac potentiates the cytotoxic impact of bortezomib on a colon cancer cell line. 122 Consideration should be given to the possibility that concurrent administration of high-dose salicylates would allow lower doses of bortezomib to be used, with equal or better clinical response.
NF-κB activation could also be influenced by targeting upstream kinases that contribute to signalsome activation. Thus, in cancers that express high tyrosine kinase activity associated with strong activation of the PI3K-Akt pathway, agents that suppress this tyrosine kinase activity would be expected to decrease signalsome activation. For example, NF-κB is usually activated in breast cancers that overexpress HER2; herceptin therapy reduces this activity in some of these cancers. 123 One should bear in mind, however, that tyrosine kinase inhibitors would be likely to exert an antiproliferative effect owing to their impact on the ras-raf-MEK-MAP kinase pathway; this in turn would be expected to decrease the responsiveness of cancers to certain chemotherapeutic agents that have cell cycle-specific activity. Thus, targeting the downstream PI3K-Akt pathway might be a more successful approach. In this regard, peroxisome proliferator activated receptor γ (PPARγ) agonists have been shown to induce increased phosphatase and tensin homolog (PTEN) activity in cancer cells that express PPARγ 124, 125 ; thus, except in cancers in which both PTEN genes have been inactivated by mutation, these agonists have the potential to down-regulate activation of signalsomes and NF-κB. In this regard, thiazolidinediones have been shown to antagonize NF-κB activity in non-small-cell lung cancer cells as well as a human colon cancer cell line. 126, 127 It should be borne in mind that Akt exerts antiapoptotic effects independent of NF-κB, phosphorylating forkhead transcription factors as well as Bad. 128 In light of the fact that oxidant stress tends to upregulate signalsome activation 129, 130 -for reasons that remain obscure-it is intriguing to note that many cancers express low-capacity membrane-bound nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase activity, analogous to that expressed by endothelial or smooth muscle cells. [131] [132] [133] In these cancers, NF-κB activity has indeed been found to be upregulated, and agents that inhibit NADPH oxidase activity suppress this activation. If well-tolerated pharmaceutical inhibitors of NADPH oxidase can be developed, these should have potential for suppressing NF-κB activity in many tumors. Various antioxidant agents, such as N-acetylcysteine and lipoic acid, can often diminish NF-κB activation in oxidatively stressed cell cultures 134, 135 ; however, the high concentrations required would probably not be clinically feasible.
A further potential avenue for down-regulating excessive NF-κB activity may be offered by tetrathiomolybdate (TM), a well-tolerated orally administrable drug that was developed to achieve copper depletion in Wilson disease. It has long been known that copper depletion has antiangiogenic effects potentially of use in cancer therapy, 136 and in both rodent studies and exploratory clinical studies, TM has indeed slowed tumor growth while suppressing the angiogenic response. [137] [138] [139] [140] Merajver and colleagues have demonstrated that TM suppresses the activation of NF-κB in SUM149 breast cancer cells, an effect associated with decreased expression of a number of proangiogenic factors. 141, 142 Furthermore, they showed that whereas TM treatment substantially slowed the growth of SUM149 tumors implanted in nude mice, it had no impact on the (much slower) growth of a modified SUM149 transfected with a mutated IκB-alpha gene that blocks NF-κB activation. 142 These findings thus suggest that the antiangiogenic and tumor-retardant effects of copper depletion are mediated by the suppression of NF-κB activity-at least in the SUM149 tumor. It will be important to determine whether these effects can be generalized to other cancers, in which case TM pretreatment (note that it takes several months to achieve clinically useful copper depletion with this agent) may have general utility as an adjuvant to cytotoxic therapies, independent of its antiangiogenic effect. Complementary interactions between TM and either doxorubicin or radiotherapy have been observed in rodents bearing transplanted tumors 143, 144 ; although these studies do not rule out the possibility that TM-mediated antiangiogenesis was primarily responsible for this complementarity, TM was shown to markedly amplify the apoptotic response of SUM149 cells to doxorubicin in vitro. 142 The impact of TM on NF-κB status is rather perplexing, inasmuch as the signaling molecules responsible for NF-κB activation are not known to be copper dependent.
Multifocal Signal Modulation Therapies as Adjuvants to Cytotoxic Therapy
A further important consideration is that up-regulation of NF-κB is no doubt only one of several strategies that wily cancers employ to achieve chemoresistance. For example, there is growing evidence that up-regulated Stat3 activity is commonly seen in a wide range of advanced cancers; this transcription factor antagonizes apoptosis by inducing the antiapoptotic proteins Bcl-xL, Mcl-1, and survivin. 145, 146 (Like NF-κB, this factor also promotes proliferation and angiogenesis through induction of cyclin D1, c-Myc, and VEGF.) Several small-molecule inhibitors of Stat3 activity have been characterized and presumably are undergoing further evaluation; it is hoped that 1 or more of these will eventually be available for clinical use. [147] [148] [149] In particular, the phytochemical cucurbitacin Q is reported to selectively inhibit Stat3 phosphorylation at a concentration of 10 µM and markedly slows the growth of 2 human tumors in nude mice at a dose of 1 mg/kg/d intraperitoneally. 147 There do not appear to be any published data regarding the toxicology or pharmacokinetics of this agent.
Increased Stat3 activity is often dependent on upstream signaling pathways in which c-Src plays an obligate role 150 ; thus, in these cancers, drugs that inhibit c-Src could be employed to suppress elevated Stat3 activity. Indeed, selective inhibitors of c-Src have been shown to diminish Stat3 activity and upregulate apoptosis in cell lines derived from human breast cancers, melanomas, and head-and-neck squamous cell tumors. [151] [152] [153] [154] Once it becomes clinically feasible to inhibit elevated Stat3 activity, combination regimens that simultaneously target both NF-κB and Stat3 would likely have a very substantial impact on capacity for apoptosis in a high proportion of chemoresistant tumors.
In cancer cells that express the forkhead transcription factor FOXO3a, mammalian target of rapamycin (mTOR) activity can suppress apoptosis by inhibiting FOXO3a activity and thereby preventing it from inducing transcription of the proapoptotic BH3-only protein Bim. [155] [156] [157] Bim appears to be of especial importance for mediating the apoptotic response to microtubule poisons such as paclitaxel. 155, [158] [159] [160] [161] Thus, pretreatment with rapamycin or its analogs can be expected to improve the response of certain tumors to paclitaxel, as has indeed been shown in cell culture studies. 162, 163 There is also recent evidence that IκB kinase-β may target FOXO3a, implying a role for salicylates in modulating Bim activity. 164 Phosphorylation of Bim by the ras-Erk1/2 pathway promotes its proteasomal degradation. 165 There are a number of reports that cox-2 activity is associated with a suppression of spontaneous apoptosis in various types of cancer cells; conversely, cox-2 inhibitors have been reported to boost the responsiveness of certain cancer cell lines to cytotoxic drugs or radiotherapy. [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] (Some of these results need to be viewed circumspectly, however, as some cox-2specific inhibitors such as celecoxib can exert proapoptotic effects that are independent of cox-2 inhibition. 185 ) Although the impact of cox-2 on apoptosis is likely mediated by PGE2 or other prostanoids, the mechanisms involved are less well understood than those that mediate the impact of NF-κB; increased expression of Bad and/or decreased expression of Bcl-2 appear to play a role in some cell lines. In non-small-cell lung cancer, cox-2 activity is reported to up-regulate insulin-like growth factor I (IGF-I) signaling at the level of the type 1 IGF receptor 186 ; IGF-I of course exerts a major antiapoptotic effect via the PI3K-Akt-mTOR pathway. Moreover, cox-2, via PGE2, can promote cellular exclusion of cancer drugs through induction of MDR1, an effect parallel to that of NF-κB. 187, 188 Inasmuch as the selective cox-2 inhibitors have now fallen into disfavor owing to their adverse impacts on vascular risk (in marked contrast to the well-documented protective effects of aspirin in this regard), the possibility of using aspirin for cox inhibition in clinical cancer should receive serious attention. (Moreover, in some tumors, cox-1 activity is the chief source of prostanoids. 189 ) These considerations suggest that, in at least some tumors, concurrent cox inhibition will amplify the proapoptotic benefit of NF-κB inhibition when salicylates-especially aspirin-are used as adjuvants to cytotoxic therapy. Alternatively, a cox-2 inhibitor (preferably in conjunction with minidose aspirin for platelet stabilization, unless contraindicated) could be used along with salsalate to achieve joint systemic inhibition of NF-κB and cox-2 while minimizing the risk for GI complications.
The chemopreventive activity of supranutritional intakes of selenium in rodents appears to reflect an up-regulation of apoptotic mechanisms mediated by methylselenol (or metabolites thereof). [190] [191] [192] In vitro studies suggest that this effect may hinge to some degree on suppression of IκB kinase activation and NF-κB activity, as well as on an amplification of p53 function and a reduction in Akt phosphorylation. [193] [194] [195] [196] [197] [198] [199] This phenomenon may have important ramifications for chemotherapy/radiotherapy. Several years ago, Vadgama and colleagues reported that selenium potentiated the response of a range of human cancer cell lines to adriamycin or taxol in vitro. 200 More recently, Lu and colleagues have shown that in concentrations as low as 1 µM, which in themselves have only a very minor impact on spontaneous apoptosis, the methylselenol precursor methylseleninic acid very markedly potentiates the apoptotic response of androgen-independent prostate cancer cell lines to a range of cytotoxic agents (topoisomerase inhibitors and paclitaxel); this effect was substantially blocked by inhibition of Jun-N-terminal kinase. 201 These findings have been replicated in vivo: in xenograftimplanted nude mice, preadministration of tolerable intakes of methylselenocysteine or selenomethionine can markedly potentiate the response of various cancers to irinotecan and other chemotherapeutic agents. 202, 203 Remarkably, such pretreatment also renders these drugs less lethal to rodents (minimum lethal dose increases). Clinical studies evaluating the impact of selenium preadministration on response to chemotherapy are now in progress at Roswell Park Cancer Institute.
Although down-regulation of NF-κB activity likely contributes to selenium's potentiation of apoptosis in these studies, this is unlikely to be the sole mechanism. Thus, Budanova and colleagues found that in prostate cancer cell lines in which NF-κB activity had been nearly abrogated by transfection with double-negative IκB (90%-95% inhibition), methylseleninic acid had a profound impact on the spontaneous rate of apoptosis, whereas this compound or dn-IκB alone had a very modest effect in this regard. 195 This raises the intriguing possibility that aspirin and organic selenium might have a complementary or synergistic effect in sensitizing cancers to cytotoxic agents. Like aspirin, organic selenium is characterized by the fact that it is inexpensive and readily available. It will not be sheer coincidence if aspirin and selenium, 2 agents with practical, documented chemopreventive activity, prove also to have important efficacy as adjuvants for cytotoxic therapy: their up-regulatory impacts on apoptotic mechanisms may underlie and rationalize this phenomenon.
Constitutive overexpression of cetain antiapoptotic proteins contributes to chemoresistance in some tumors. Antisense agents that target bcl-2 or survivin are being evaluated preclinically. [204] [205] [206] There are several reports that calcitriol, as well as other agonists for the vitamin D receptor that are less calcemic, can boost the apoptotic response to radiation in human prostate and breast cancer cell lines, in concentrations that in themselves have little impact on spontaneous apoptosis. [207] [208] [209] [210] This effect might be mediated by modulation of the expression of members of the bcl-2 family, 211-216 whose expression is known to have a major impact on cellular radiosensitivity. [217] [218] [219] [220] [221] [222] A least a portion of this effect might be secondary to increased production of IGFBP-3, [223] [224] [225] [226] which, through mechanisms that are independent of IGF-I, can boost expression of proapoptotic Bax and Bad while suppressing expression (or activity) of antiapoptotic bcl-2 and bcl-xL in certain cell lines. [227] [228] [229] [230] (The associated local down-regulation of IGF-I activity may also play a role by relieving an inhibitory phosphorylation of Bad. 231, 232 ) Indeed, IGFBP-3 has itself been shown to have radiosensitizing activity. 227 Thus, preadministration of calcitriol-or less calcemic paricalcitol 209,233 -might find utility in clinical radiotherapy. Theoretically, when calcitriol-responsive cancers continue to express the 1-α-hydroxylase activity present in their tissue of origin, preadministration of high-dose vitamin D might provide similar benefit.
The possibility that calcitriol could analogously boost cancer responsiveness to certain cytotoxic drugs also merits evaluation. Indeed, calcitriol or calcitriol analogs have been shown to potentiate the cell killing achieved with taxanes, doxorubicin, adriamycin, or platinum compounds in human breast and prostate cancer cell cultures. [234] [235] [236] [237] [238] [239] Most impressively, in the recent ASCENT clinical trial, 239 preadministration of high-dose calcitriol has been found to markedly improve the outcome of docetaxel therapy in patients with hormone-resistant prostate cancer; survival increased by 49%, while the occurrence of significant chemotherapy side effects was diminished.
The activity of tyrosine kinase growth factor receptors expressed by a given tumor can influence responsiveness to chemotherapy, both by regulating apoptosis and by determining the fraction of tumor cells in chemosensitive phases of the cell cycle. Thus, growth factors such as IGF-I or epidermal growth factor, by stimulating PI3K-Akt-mTor and ras-Erk1/2 pathways, act in various ways to suppress apoptosisby phosphorylation of Bad and of FOXO3a, for example. [240] [241] [242] On the other hand, growth factor activity conceivably could enhance the responsiveness of tumors to certain cycle-specific cytotoxins by increasing the fraction of cells in the S and M phases. Thus, measures that down-regulate tumor growth factor activities (eg, tyrosine kinase inhibitors, low-fat vegan diet 243, 244 ) during chemotherapy might or might not improve responsiveness, depending on the cell cycle specificity of the chemotherapy employed. In practice, though, down-regulation of IGF-I activity has been reported to potentiate the apoptotic responsiveness of many cancer cell lines to a range of cytotoxins, including 5-FU, methotrexate, tamoxifen, camptothecin, doxorubicin, etoposide, carboplatin, and ionizing radiation. [245] [246] [247] [248] [249] [250] [251] Analogously, herceptin has been found to boost the responsiveness of ErbB2overexpressing breast cancer cell lines to paclitaxel and radiotherapy. 252, 253 Thus, the published evidence suggests that concurrent antagonism of growth factor signaling is more likely than not to enhance responsiveness to cytotoxic therapy. In this regard, it is pertinent to note that systemic IGF-I activity is downregulated by a low-fat, moderate-protein vegan diet complemented by aerobic exercise training and can be decreased more acutely by fasting. 243, 244, 254 Several small G proteins typically activated by growth factor stimulation-most notably Ras and RhoA-transmit antiapoptotic signals; Ras can activate both the Raf-Erk1/2 and the PI3K-Akt pathways, whereas RhoA promotes bcl-2 expression while inhibiting that of Bid. [255] [256] [257] [258] Transfecting cells with wildtype or constitutively active RhoA decreases their sensitivity to a range of cytotoxic agents, although this increases sensitivity to vincristine. 259 The activity of these G proteins is contingent on posttranslational isoprenylation and thus can be suppressed by inhibitors of prenyltransferases or by measures that reduce the availability of farnesyl and geranylgeranyl pyrophosphates. Since insulin promotes phosphorylations of prenyltransferases that boost their activity, 260, 261 lifestyle and supplementation strategies that minimize diurnal insulin secretion should down-regulate prenyltransferase activities; direct inhibitors of prenyltransferases are not yet clinically available. The availability of isoprenyl pyrophosphates can be reduced by drugs or nutraceuticals that either directly inhibit HMG-CoA reductase (ie, statins) or that down-regulate its expression. The latter category includes certain terpenoid phytochemicals, such as γ-tocotrienol and limonene, as well as policosanol. [262] [263] [264] [265] Mo and Elson have suggested that inasmuch as many cancers appear to be unusually sensitive to the impact of terpenes on HMG-CoA reductase expression, concurrent administration of terpenes and a moderate dose of a statin may be a rational way to suppress tumor HMG-CoA reductase activity while avoiding unacceptable systemic toxicity; they report that clinically achievable concentrations of lovastatin and γ-tocotrienol, when administered jointly, have a marked impact on the in vitro proliferation of a wide range of cancer cell lines. 266 In this regard, Nagourney has reported that tolerable intakes of limonene and lovastatin induced objective remission in several patients with advanced cancer and restored chemosensitivity in several patients who had become chemoresistant. 267 Thus, prenylation inhibition has potential as a strategy for slowing cancer spread as well as for boosting chemosensitivity.
Multifocal signal modulation therapy (MSMT) has been defined as a strategy for controlling cancer growth and spread by targeting multiple signaling pathways that regulate proliferation, apoptosis, migration, and angiogenesis. [268] [269] [270] What is proposed here is a special type of MSMT intended to up-regulate apoptotic mechanisms in the context of concurrent cytotoxic therapy-a proapoptotic MSMT. Ultimately, it may prove possible to custom design such regimens so that they address the needs of a particular tumor; microarrays and other techniques could be used to determine which up-regulated signaling pathways are most responsible for chemoresistance and which thus need to be targeted. Presumably, the antiproliferative impacts of such regimens should be minimized when cell cycle-specific cytotoxins are employed. Moreover, we must bear in mind that even in the context of up-regulated apoptotic mechanisms, the low proportion of cycling cells in some chemoresistant tumors places an upper limit on the extent of cell kill that can be achieved by cell cyclespecific agents.
Extending the Concept to Metronomic Therapy
In the foregoing, it has been assumed that cytotoxic therapy is targeting cancer cells. However, so-called metronomic chemotherapy, in which low doses of various cytotoxins are administered at least once weekly or even daily, targets the endothelial cells and fragile developing capillaries in tumors, which typically are highly sensitive to sustained chemotherapeutic attack [271] [272] [273] [274] [275] [276] ; this high sensitivity may reflect, at least in part, p53-mediated induction of thrombospondin-1, an antiangiogenic factor that induces apoptosis specifically in endothelial cells via interaction with the CD36 receptor expressed by these cells. 277, 278 This raises the issue as to what extent the strategies discussed above boost the responsiveness of the nascent tumor vasculature to metronomic therapies. Although little research has yet addressed this question, it can be noted that NF-κB plays a role in suppressing apoptosis in endothelial cells, [279] [280] [281] [282] that the endothelial cells in tumors (unlike those in most tissues) may be responsive to calcitriol, 283 that organic selenium compounds can exert apoptotic effects on endothelial cells, 284, 285 and that IGF-I functions directly-and indirectly-as a survival factor for these cells. [286] [287] [288] Moreover, in light of the key role that VEGF plays in endothelial cell survival during angiogenesis, it is intriguing to note that VEGF antagonism can substantially enhance the therapeutic response to metronomic therapy in xenografted rodents. 289, 290 A portion of VEGF's antiapoptotic influence on endothelial cells 291-294 may be mediated by NF-κB activation [295] [296] [297] and thus may be susceptible to antagonism by salicylate and possibly silibinin 280 ; indeed, it is probably not sheer coincidence that many of the survival proteins up-regulated by VEGF in endothelial cells, such as bcl-2, survivin, and XIAP, are transcriptional targets of NF-κB.
Since VEGF appears to have a major impact on the susceptibility of tumor endothelial cells to metronomically administered cytotoxins, it is likely that tyrosine kinase inhibitors or monoclonal antibodies that target VEGF signaling will have utility as adjuvants to metronomic therapy. 289, 290 Moreover, it should be noted that various nutraceuticals recommended for use in angiostatic therapy 298, 299 may influence VEGF activity. Thus, the primary green tea catechin EGCG can inhibit VEGFR-2 (KDR/flk-1) activity in high physiological concentrations (∼1 µM) 300 ; the eicosapentaenoic acid in fish oil can inhibit the expression of this receptor 301, 302 ; high-dose glycine may boost the activity of a tyrosine phosphatase, which targets this receptor (M. F. McCarty, unpublished data, 2005); and silymarin, selenium, and IGF-I down-regulation have the potential to suppress the production of VEGF by tumor cells. 287, [303] [304] [305] The drugs tetrathiomolybdate and salicylate can be expected to inhibit VEGF production by some tumors via suppression of NF-κB activity. [306] [307] [308] There may thus be a number of clinically feasible measures that could boost the effectiveness of metronomic therapy by antagonizing VEGF signaling or by increasing the apoptotic responsiveness of endothelial cells through other mechanisms.
The angiogenic process entails recruitment of mural cells (pericytes, smooth muscle cells) by nascent capillary tubes; endothelial production of platelet-derived growth factor (PDGF) plays a key role in this process. [309] [310] [311] Association with mural cells renders endothelial cells much less vulnerable to apoptosis-in part owing to pericyte expression of angiopoeitin-1-and an up-regulation of mural cell recruitment is observed in tumors that have become less responsive to metronomic therapy during longterm treatment. 309, [312] [313] [314] [315] [316] Tyrosine kinase inhibitors that are relatively specific for the PDGF receptor, including the approved drug imatinib (Gleevec), have been shown to boost and prolong the efficacy of metronomic therapy in rodent tumor models, presumably by suppressing mural cell recruitment. 317 Inhibitors of NF-κB activation such as salicylate may have some utility in this regard as well, as this transcription factor plays a key role in endothelial production of PDGF. [318] [319] [320] In low micromolar concentrations, EGCG inhibits the tyrosine kinase activity of the PDGF receptor [321] [322] [323] ; the impact at physiologically achievable concentrations would be at best modest but possibly worthwhile. PGDF also has a direct autocrine impact on endothelial growth and survival and acts as an autocrine growth factor for some cancers; thus, PDGF and its receptor are emerging as useful targets in cancer management. 290, [324] [325] [326] [327] Imatinib, owing to the fact that it is orally administrable and well tolerated, may be particularly useful for suppressing PDGF activity.
